Date/Time
Location
The opioid epidemic continues to be a major public health crisis, driven largely by fentanyl and other synthetic opioids. Buprenorphine is a partial opioid agonist that binds to opioid receptors in the brain. Its unique pharmacological profile, characterized by a ceiling effect, limits the risk of overdose and makes it a safer alternative to full agonists like methadone.
Newer formulations and updated initiation strategies can help stabilize patients and support long-term recovery. The session can be helpful to all clinicians who care for individuals with opioid use. Clinicians can educate and reassure their patients on these updates and guide them to treatment.
Learning Objectives
- Describe the current opioid epidemic landscape
- Assess buprenorphine pharmacology
- Describe unique challenges in buprenorphine initiation
- Define clinical practice and micro (low dose) and macro (high dose) initiation
Time: 10:00 a.m. — 11:30 a.m. EST
Location: Virtual
Presenter: Vishesh Agarwal, MD
Dr. Vishesh Agarwal is an award winning board-certified general adult psychiatrist, with additional board certification in addiction psychiatry and obesity medicine. He received the Delaware Today Top doctors award in 2022. Along with his clinical work, Dr. Agarwal supervises and mentors trainee physicians and student learners. He is an invited speaker at regional, and national conferences, and has published in peer-reviewed journals.
*CONTACT HOUR ELIGIBILITY
In order to be eligible for the contact hours/certificate of attendance, you must join the live webinar in the Zoom platform.
Contact Hours (Certificate of Attendance): up to 1.25 for attending the entire session.
If you are having issues accessing the room/application at the time of the event, please email webinars@danyainstitute.org at the start of the webinar so that we can assist you.
Registration questions email training@danyainstitute.org or call 240-645-1145.